{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:37:56Z","timestamp":1791909476769,"version":"4.3.4"},"reference-count":20,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous areas of the brain, including the cerebral cortex and thalamus. With legislation introduced in 1992, more work is being done to further understand the implications of psilocybin use in a number of disease states. Certain mental health disease states and symptoms have been studied, including depressed mood, anxiety disorders, obsessive-compulsive disorder, alcohol use disorder, and tobacco use disorder. This article provides an in-depth review of the study design and results of psilocybin in each of these conditions and discusses the clinical potential for use.<\/jats:p>","DOI":"10.9740\/mhc.2017.01.024","type":"journal-article","created":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T14:05:44Z","timestamp":1483452344000},"page":"24-28","source":"Crossref","is-referenced-by-count":66,"title":["Clinical potential of psilocybin as a treatment for mental health conditions"],"prefix":"10.9740","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-410X","authenticated-orcid":false,"given":"Jeremy","family":"Daniel","sequence":"first","affiliation":[{"name":"(Corresponding author) Assistant Professor, South Dakota State University College of Pharmacy, Sioux Falls, South Dakota; Psychiatric Clinical Pharmacist, Avera Behavioral Health Center, Sioux Falls, South Dakota, Jeremy.Daniel@avera.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-2295","authenticated-orcid":false,"given":"Margaret","family":"Haberman","sequence":"first","affiliation":[{"name":"Psychiatric Clinical Pharmacist, Avera Behavioral Health Center, Sioux Falls, South Dakota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"issue":"4","key":"2020060307302622600_i2168-9709-7-1-24-b01","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict Biology"},{"key":"2020060307302622600_i2168-9709-7-1-24-b02","first-page":"6.5","article-title":"All arounders","author":"Inaba","year":"2014","journal-title":"Uppers, downers, all arounders \u2013 physical and mental effects of psychoactive drugs. 8th ed"},{"issue":"4","key":"2020060307302622600_i2168-9709-7-1-24-b03","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/2045125314527985","article-title":"Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles","volume":"4","author":"Baumeister","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"issue":"6","key":"2020060307302622600_i2168-9709-7-1-24-b04","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2020060307302622600_i2168-9709-7-1-24-b05","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2020060307302622600_i2168-9709-7-1-24-b06","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/1570159X13666141210222409","article-title":"Recreational use, analysis and toxicity of tryptamines","volume":"13","author":"Tittarelli","year":"2015","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"2020060307302622600_i2168-9709-7-1-24-b07","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/02791072.2014.873688","article-title":"The Heffter Research Institute: past and hopeful future","volume":"46","author":"Nichols","year":"2014","journal-title":"J Psychoactive Drugs"},{"issue":"11","key":"2020060307302622600_i2168-9709-7-1-24-b08","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J Psychopharmacol"},{"key":"2020060307302622600_i2168-9709-7-1-24-b09","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th text revision. Washington: American Psychiatric Association;2000."},{"issue":"3","key":"2020060307302622600_i2168-9709-7-1-24-b10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/0269881114568039","article-title":"Psychedelics not linked to mental health problems or suicidal behavior: a population study","volume":"29","author":"Johansen","year":"2015","journal-title":"J Psychopharmacol"},{"issue":"3","key":"2020060307302622600_i2168-9709-7-1-24-b11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","article-title":"Harm potential of magic mushroom use: a review","volume":"59","author":"van Amsterdam","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"issue":"3","key":"2020060307302622600_i2168-9709-7-1-24-b12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"2020060307302622600_i2168-9709-7-1-24-b13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1177\/0269881115598338","article-title":"Psilocybin, psychological distress, and suicidality","volume":"29","author":"Hendricks","year":"2015","journal-title":"J Psychopharmacol"},{"key":"2020060307302622600_i2168-9709-7-1-24-b14","article-title":"Population Data\/NSDUH","author":"Substance Abuse and Mental Health Services Administration [Internet]","year":"2016"},{"issue":"6","key":"2020060307302622600_i2168-9709-7-1-24-b15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2020060307302622600_i2168-9709-7-1-24-b16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"2020060307302622600_i2168-9709-7-1-24-b17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/02791072.2014.963754","article-title":"Psilocybin and obsessive compulsive disorder","volume":"46","author":"Wilcox","year":"2014","journal-title":"J Psychoactive Drugs"},{"issue":"11","key":"2020060307302622600_i2168-9709-7-1-24-b18","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"2020060307302622600_i2168-9709-7-1-24-b19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"issue":"11","key":"2020060307302622600_i2168-9709-7-1-24-b20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/1\/24\/2095655\/mhc_2017_01_024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/1\/24\/2095655\/mhc_2017_01_024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T11:22:26Z","timestamp":1731669746000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/7\/1\/article-p24.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2017.01.024","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,1]]}}}